Biogen and Ionis Receive the US FDA's Approval of Qalsody (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis
4.9
$ 15.99
In stock
(597)
Product Description
Rise of the Genomic Medicine Era in Amyotrophic Lateral Sclerosis - Practical Neurology
FDA Expected to Decide on Tofersen Approval for SOD1-ALS in January
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Amyotrophic Lateral Sclerosis Pipeline
amyotrophic lateral sclerosis Archives - DelveInsight
Qalsody: New Drug for Amyotrophic Lateral Sclerosis with SOD1 Mutation • BioPharma Media
Latest FDA Approvals - Biocom California
Biogen and Ionis Receive the US FDA's Approval of Qalsody (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for
How MDA Invests in Research Success - Quest
ALS drug tofersen will face FDA advisors, says Biogen
FDA greenlights Biogen's Qalsody for rare, genetic form of ALS
How High Is the Bar for Future ALS Treatments? Although
US FDA flexibility the question as Nurown goes before adcom
